Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
1:1 active treatment: placebo, blinded trial, evaluating the effect of a 4-week treatment period with topical C-82 on skin expression of two gene biomarker surrogates (THBS1 and COMP) for the modified Rodnan skin score (MRSS). Study subjects will be randomized to apply the active study medication daily for 4 weeks to either the right or left forearm and placebo to the contralateral forearm.
Epistemonikos ID: 7428fc6edb06b19e9a6eea6ab49b48c79cc2f55f
First added on: May 12, 2024